Literature DB >> 2311166

Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.

G Los1, P H Mutsaers, W J Lenglet, G S Baldew, J G McVie.   

Abstract

The spatial distribution of platinum (Pt) in the kidney was studied by an autoradiographic technique, in which cisplatin (CDDP) was replaced by 195mPt-labeled CDDP, and by proton-induced X-ray emission (PIXE). Although both studies demonstrated comparable spatial distribution patterns, PIXE had the advantage that Pt concentrations could be determined quantitatively, in contrast to the relative information obtained by the autoradiographic technique. Using PIXE, the distribution of Pt in i.p. tumors was studied after i.p. administration of CDDP. The highest Pt concentrations were always found on the periphery of tumors, indicating that the periphery was exposed to a higher drug concentration than the center. Dose was correlated to the concentration of CDDP at both the center and the periphery (r = 0.99). The Pt concentration in the periphery was usually higher by a factor of 2-3 after i.p. administration than after i.v. treatment, whereas in the center of the tumor no concentration difference could be detected. The penetration depth of CDDP lay between 1 and 2 mm and was calculated from the differences in Pt concentration after i.p. and i.v. treatment. This indicates that the effective advantage of i.p. chemotherapy with CDDP in cases of cancers limited to the peritoneal cavity is accentuated at the periphery of the tumor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311166     DOI: 10.1007/bf00686048

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  The nephrotoxic effects of cis-diammine-dichloroplatinum (II) (NSC-119875) in male F344 rats.

Authors:  J M Ward; K A Fauvie
Journal:  Toxicol Appl Pharmacol       Date:  1976-12       Impact factor: 4.219

2.  Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.

Authors:  R F Ozols; G Y Locker; J H Doroshow; K R Grotzinger; C E Myers; R C Young
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

Review 3.  Intraperitoneal chemotherapy: a review.

Authors:  D E Brenner
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

4.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

5.  Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.

Authors:  M Markman; S Cleary; W E Lucas; S B Howell
Journal:  J Clin Oncol       Date:  1985-07       Impact factor: 44.544

6.  Experimental and clinical results with intraperitoneal cisplatin.

Authors:  W W ten Bokkel Huinink; R Dubbelman; E Aartsen; H Franklin; J G McVie
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

7.  The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies.

Authors:  J L Speyer; C E Myers
Journal:  Recent Results Cancer Res       Date:  1980

8.  Heuristic modeling of drug delivery to malignant brain tumors.

Authors:  V A Levin; C S Patlak; H D Landahl
Journal:  J Pharmacokinet Biopharm       Date:  1980-06

Review 9.  Minireview. The nephrotoxicity of cisplatin.

Authors:  R S Goldstein; G H Mayor
Journal:  Life Sci       Date:  1983-02-14       Impact factor: 5.037

10.  Proliferative lesions found in rat kidneys after a single dose of cisplatin.

Authors:  R E Bulger; D C Dobyan
Journal:  J Natl Cancer Inst       Date:  1984-11       Impact factor: 13.506

View more
  33 in total

Review 1.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  Kenneth Jaaback; Nick Johnson; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.

Authors:  Tristan D Yan; Christopher Qian Cao; Stine Munkholm-Larsen
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

3.  High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis.

Authors:  Philippe Esquis; David Consolo; Guy Magnin; Philippe Pointaire; Philippe Moretto; Maria Dolores Ynsa; Jean-Luc Beltramo; Carole Drogoul; Michel Simonet; Laurent Benoit; Patrick Rat; Bruno Chauffert
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

4.  Description of a novel approach for intraperitoneal drug delivery and the related device.

Authors:  Wiebke Solaß; Alexander Hetzel; Giorgi Nadiradze; Emil Sagynaliev; Marc A Reymond
Journal:  Surg Endosc       Date:  2012-05-12       Impact factor: 4.584

5.  Preclinical imaging characteristics and quantification of Platinum-195m SPECT.

Authors:  E A Aalbersberg; B J de Wit-van der Veen; O Zwaagstra; K Codée-van der Schilden; E Vegt; Wouter V Vogel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-11       Impact factor: 9.236

Review 6.  Peritoneal Metastases from Gastrointestinal Cancer.

Authors:  Paul H Sugarbaker
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

Review 7.  Intraoperative imaging in ovarian cancer: fact or fiction?

Authors:  Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

8.  Effect of intraperitoneal cetuximab administration on colonic anastomosis and early postoperative adhesion formation in a rat model.

Authors:  Atilla Kurt; Hasan Karanlık; Sinan Soylu; İlker Özgür; Hilal Oğuz Soydinç; Derya Duranyıldız; Vakur Olgaç; Fatma Şen; Oktar Asoğlu
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01

9.  A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.

Authors:  Maurie Markman; Jerome Belinson
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-21       Impact factor: 4.553

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.